Carrie Koenigsfeld, PharmD, FAPhA, reviews the pivotal findings from the AReSVi-006 trial that supported the approval of the adjuvanted RSV vaccine, including its efficacy in preventing lower respiratory tract RSV, associated adverse events, and important study limitations that may have influenced the results.
An RSV medical expert provides an overview of the RENOIR trial, which investigated the efficacy and safety of an adjuvanted RSV vaccine in adults aged 60 years and older, focusing on the vaccine's effectiveness in preventing RSV-associated lower respiratory tract infections and presenting other crucial findings from the study.
Carrie Koenigsfeld, PharmD, FAPhA, highlights the main findings from the MATISSE trial, which evaluated the safety and efficacy of a non-adjuvanted RSV vaccine administered to pregnant women, presenting data that suggests the vaccine's effectiveness in preventing severe RSV in infants and discussing the observed adverse events in both mothers and infants.
Carrie Koenigsfeld, PharmD, FAPhA, explores the potential contraindications that may preclude individuals from receiving an RSV vaccine.
A medical expert examines the ideal timing for administering RSV vaccines to adults over 60 or pregnant women, emphasizing the importance of proper timing for a single-dose vaccine and outlining the necessary steps to be taken if a pregnant woman inadvertently receives an adjuvanted RSV vaccine.
Carrie Koenigsfeld, PharmD, FAPhA, shares strategies that pharmacists can use to effectively tackle vaccine hesitancy, particularly concerning newer vaccines such as the RSV vaccine, through building trust with patients to encourage informed decision-making.
Cherokee Layson-Wolf, PharmD, BCACP, FAPhA, provides an overview of respiratory syncytial virus (RSV), highlighting disease transmission, incidence, symptoms, and factors that indicate higher risk of hospitalization.
An expert on RSV discusses symptoms that warrant emergent medical care and the overall impact of RSV on older adults or immunocompromised individuals.
Cherokee Layson-Wolf, PharmD, BCACP, FAPhA, outlines evidence-based measures that can be implemented to prevent or minimize the transmission of RSV.
Focusing on the preparation of RSV vaccines, Cherokee Layson-Wolf, PharmD, BCACP, FAPhA, provides detailed insights on the differences between the adjuvanted and nonadjuvanted vaccines.
An expert on RSV vaccination provides insights on barriers that prevent the uptake of RSV vaccines and preventative measure in the pipeline for RSV.
Cherokee Layson-Wolf, PharmD, BCACP, FAPhA, provides key takeaways and advice to pharmacists on the administration of RSV vaccines.
